Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

Treatment of Pudendal Neuralgia

Pharmacological Management

  • The American College of Physicians recommends initiating treatment with tricyclic antidepressants (nortriptyline or desipramine) or SNRIs (duloxetine, venlafaxine) as first-line agents, combined with gabapentin or pregabalin, following the established neuropathic pain treatment algorithm 1
  • Tricyclic antidepressants should be started at low doses at bedtime, titrating slowly over 6-8 weeks, including 2 weeks at maximum tolerated dose (limit to <100 mg/day when possible), and patients over 40 years old should be screened with an ECG due to cardiac toxicity risk 1
  • SNRIs, such as duloxetine or venlafaxine, can be used as alternatives with better tolerability profiles 1
  • Calcium channel α2-δ ligands, including gabapentin or pregabalin, can be used for neuropathic pain management 1, 2
  • The American Academy of Neurology recommends using topical lidocaine for localized peripheral neuropathic pain, which can be used alone or combined with systemic agents 1

Adjunctive Therapies

  • Physical therapy modifications, including manual physical therapy targeting pelvic floor trigger points, muscle contractures, and scar tissue, should be used, while avoiding standard Kegel exercises which can worsen symptoms 3
  • Behavioral modifications, such as avoiding tight-fitting clothing, managing constipation, and implementing stress management practices, can help alleviate symptoms 3

Critical Pitfalls to Avoid

  • The American Urological Association advises against using standard Kegel exercises in pelvic floor rehabilitation as they worsen symptoms in some patients 3
  • The American Heart Association recommends not prescribing tricyclic antidepressants without cardiac screening in patients over 40 years or with cardiac history 1
  • The American Academy of Pain Medicine states that opioids are second-line for neuropathic pain conditions and should not be first-line therapy 2

REFERENCES